Karyopharm Therapeutics, Inc. has entered into a preferred provider agreement with Clinipace Worldwide for the management of several clinical programs for oncology, wound healing, and other diseases. Clinipace will provide services under its digital CRO model aimed at accelerating a personalized approach to targeted therapies through collaboration, higher data quality, and reduced development costs.
“It is our mission to foster scientific creativity with pioneering technologies and developmental approaches within an innovative culture,” said Sharon Shacham, Ph.D., MBA, Karyopharm’s founder, president and chief scientific officer. “By partnering with a like-minded technology-driven company like Clinipace, we believe we can help accelerate our first-in-class small molecule modulators into effective targeted therapeutics for life threatening conditions.”
“As tailored therapies such as those Karyopharm have under development become more prominent, drug developers must find increasingly innovative ways to help bring their products to market in the most effective and efficient manner,” said Jeff Williams, chief executive officer and co-founder, Clinipace Worldwide. “Working with a technology-enabled digital CRO (dCRO) provides our clients with a significant level of information sharing that helps increase collaboration, improves data quality, and reduces their overall development costs.”